BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 33030731)

  • 1. The immune complex p53 protein/anti-p53 autoantibodies in the pathogenesis of ovarian serous carcinoma.
    Mielczarek-Palacz A; Sikora J; Kondera-Anasz Z; Smycz-Kubańska M; Englisz A; Strzelczyk J; Kabut J
    Ginekol Pol; 2020; 91(9):519-253. PubMed ID: 33030731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
    Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer.
    Marx D; Frey M; Zentgraf H; Adelssen G; Schauer A; Kuhn W; Meden H
    Cancer Detect Prev; 2001; 25(2):117-22. PubMed ID: 11341346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Concentration of soluble ligand for receptor CD30 (sCD30L)--marker of apoptosis in women with ovarian tumor].
    Mielczarek-Palacz A; Kondera-Anasz Z; Sikora J; Sodowski K; Switała J; Kubina R
    Ginekol Pol; 2009 Jul; 80(7):494-7. PubMed ID: 19697811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma.
    Abendstein B; Marth C; Müller-Holzner E; Widschwendter M; Daxenbichler G; Zeimet AG
    Cancer; 2000 Mar; 88(6):1432-7. PubMed ID: 10717627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.
    Yu-Rice Y; Edassery SL; Urban N; Hellstrom I; Hellstrom KE; Deng Y; Li Y; Luborsky JL
    Reproduction; 2017 Mar; 153(3):277-284. PubMed ID: 27965399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
    Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
    Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the Concentration of Markers Participating in the Regulation of the Apoptosis Receptor Pathway Involving Soluble Tumour Necrosis Factor Ligand inducing Apoptosis (sTRAIL) and Osteoprotegerin (OPG) in the Serum of Women with Ovarian Cancer-Participation in Pathogenesis or a Possible Clinical Use?
    Mielczarek-Palacz A; Kondera-Anasz Z; Smycz-Kubańska M
    Cells; 2020 Mar; 9(3):. PubMed ID: 32143328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of prognostic factors for the extent of vascularity of serous ovarian cancer on the basis of CD34 antigen expression].
    Blok R; Blok K; Jeleń M; Gryboś M
    Ginekol Pol; 2004 Feb; 75(2):91-8. PubMed ID: 15108579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 11. p53 autoantibodies in the sera, cyst and ascitic fluids of patients with ovarian cancer.
    Montenarh M; Harloziñska A; Bar JK; Kartarius S; Günther J; Sedlaczek P
    Int J Oncol; 1998 Sep; 13(3):605-10. PubMed ID: 9683801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibody biomarkers for the detection of serous ovarian cancer.
    Katchman BA; Chowell D; Wallstrom G; Vitonis AF; LaBaer J; Cramer DW; Anderson KS
    Gynecol Oncol; 2017 Jul; 146(1):129-136. PubMed ID: 28427776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis.
    Høgdall EV; Høgdall CK; Blaakaer J; Heegaard NH; Glud E; Christensen L; Bock JE; Nørgaard-Pedersen B; Wiik A; Kjaer SK
    APMIS; 2002 Aug; 110(7-8):545-53. PubMed ID: 12390412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation.
    Green JA; Robertson LJ; Campbell IR; Jenkins J
    Cancer Detect Prev; 1995; 19(2):151-5. PubMed ID: 7750102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer.
    Nijman HW; van Diest PJ; Poort-Keesom RJ; von Mensdorff-Pouilly S; Verstraeten RA; Kummer A; Meijer CJ; Melief CJ; Hilgers J; Kenemans P
    Eur J Obstet Gynecol Reprod Biol; 2001 Jan; 94(1):114-20. PubMed ID: 11134836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
    Leffers N; Lambeck AJ; de Graeff P; Bijlsma AY; Daemen T; van der Zee AG; Nijman HW
    Gynecol Oncol; 2008 Sep; 110(3):365-73. PubMed ID: 18571704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers.
    Katchman BA; Barderas R; Alam R; Chowell D; Field MS; Esserman LJ; Wallstrom G; LaBaer J; Cramer DW; Hollingsworth MA; Anderson KS
    Proteomics Clin Appl; 2016 Jul; 10(7):720-31. PubMed ID: 27121307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors.
    Bar JK; Słomska I; Rabczyńki J; Noga L; Gryboś M
    Int J Gynecol Cancer; 2009 Nov; 19(8):1322-8. PubMed ID: 20009884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer.
    Gadducci A; Ferdeghini M; Buttitta F; Cosio S; Fanucchi A; Annicchiarico C; Gagetti O; Bevilacqua G; Genazzani AR
    Gynecol Oncol; 1999 Jan; 72(1):76-81. PubMed ID: 9889034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.